Showing 341 - 360 results of 99,368 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 1.43s Refine Results
  1. 341

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  2. 342

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353
  14. 354
  15. 355
  16. 356

    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

    Published 2021
    “…Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
  17. 357
  18. 358
  19. 359
  20. 360